Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared a post on X:
“Fludarabine, cyclophosphamide and 2 Gy TBI with PT-Cy as a single platform for haplo and unrelated donor allo-SCT in older AML or MDS patients | Bone Marrow Transplantation
Study: 203 AML/high-risk MDS patients (2015–2024) received FluCyTBI plus PTCy allo-SCT.
Median age: 69 years; Haplo 64%; Mismatched UD 18%; Matched UD 18%
Day +100 grade III–IV aGVHD: 8%
3-year moderate/severe cGVHD: 18%
3-year NRM: 15%
3-year overall survival: 62%
Key finding: Monosomal karyotype was the only predictor of worse survival.
Conclusion: FluCyTBI plus PTCy showed favorable safety and efficacy in both haplo and unrelated donor transplants, with donor age 35 years or older and female-to-male mismatch influencing GVHD risk.”
Title: Fludarabine, cyclophosphamide and 2 Gy TBI with PT-Cy as a single platform for haplo and unrelated donor allo-SCT in older AML or MDS patients
Authors: Guillaume Berton, Sabine Fürst, Benjamin Bouchacourt, Samia Harbi, Charlotte Nykolyszyn, Cassandre Petit-Deharo, Micha Srour, Ilaria Pili, Camille Rouzaud, Clémence Demerlé, Boris Calmels, Claude Lemarié, Anne-Line Château, Sophie Simon, Marie Anne Hospital, Sylvain Garciaz, Christian Chabannon, Pierre-Jean Weiller, Didier Blaise, Raynier Devillier
Other articles featuring Mostafa Faisal on OncoDaily.